File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Thymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
  • Basic View
  • Metadata View
  • XML View
TitleThymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
 
AuthorsLau, GKK3
Nanji, A3
Hou, J1
Fong, DYT2
Au, WS2
Yuen, ST3
Lin, M2
Kung, HF2
Lam, SK3
 
KeywordsFamciclovir
HBV
Immune tolerant
Thymosin-α1
 
Issue Date2002
 
CitationJournal Of Viral Hepatitis, 2002, v. 9 n. 4, p. 280-287 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
 
AbstractWe examined whether combination therapy with thymosin-α1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation. We studied 32 hepatitis B e antigen positive patients in the immune-tolerant phase of infection, treated with 26-weeks combination therapy of famciclovir and thymosin-α1 (group 1). Thirty-two patients who received 26-weeks famciclovir monotherapy (group 2) and another 32 patients who received no treatment (group 3), served as controls. Peripheral blood mononuclear cell proliferation and cytokine secretion in response to recombinant HBV core and surface antigen and serial serum HBV-DNA, were assayed. No significant difference in adverse events were observed among the three groups. By week 26, the median reduction in group 1 (0.94 log 10 copies/mL) was greater than group 2 (0.70 log 10 copies/mL, P < 0.001). Five (15.6%) patients in group 1 at 52 weeks (median range 13-78 weeks) and none in group 2 or 3 experienced hepatitis B e antigen seroconversion (P = 0.053). Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored.
 
ISSN1352-0504
2013 Impact Factor: 3.307
 
DOIhttp://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLau, GKK
 
dc.contributor.authorNanji, A
 
dc.contributor.authorHou, J
 
dc.contributor.authorFong, DYT
 
dc.contributor.authorAu, WS
 
dc.contributor.authorYuen, ST
 
dc.contributor.authorLin, M
 
dc.contributor.authorKung, HF
 
dc.contributor.authorLam, SK
 
dc.date.accessioned2012-10-08T03:10:46Z
 
dc.date.available2012-10-08T03:10:46Z
 
dc.date.issued2002
 
dc.description.abstractWe examined whether combination therapy with thymosin-α1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation. We studied 32 hepatitis B e antigen positive patients in the immune-tolerant phase of infection, treated with 26-weeks combination therapy of famciclovir and thymosin-α1 (group 1). Thirty-two patients who received 26-weeks famciclovir monotherapy (group 2) and another 32 patients who received no treatment (group 3), served as controls. Peripheral blood mononuclear cell proliferation and cytokine secretion in response to recombinant HBV core and surface antigen and serial serum HBV-DNA, were assayed. No significant difference in adverse events were observed among the three groups. By week 26, the median reduction in group 1 (0.94 log 10 copies/mL) was greater than group 2 (0.70 log 10 copies/mL, P < 0.001). Five (15.6%) patients in group 1 at 52 weeks (median range 13-78 weeks) and none in group 2 or 3 experienced hepatitis B e antigen seroconversion (P = 0.053). Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Viral Hepatitis, 2002, v. 9 n. 4, p. 280-287 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
 
dc.identifier.doihttp://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
 
dc.identifier.epage287
 
dc.identifier.hkuros78774
 
dc.identifier.hkuros67333
 
dc.identifier.issn1352-0504
2013 Impact Factor: 3.307
 
dc.identifier.issue4
 
dc.identifier.scopuseid_2-s2.0-0036633685
 
dc.identifier.spage280
 
dc.identifier.urihttp://hdl.handle.net/10722/167738
 
dc.identifier.volume9
 
dc.languageeng
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofJournal of Viral Hepatitis
 
dc.relation.referencesReferences in Scopus
 
dc.subjectFamciclovir
 
dc.subjectHBV
 
dc.subjectImmune tolerant
 
dc.subjectThymosin-α1
 
dc.titleThymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lau, GKK</contributor.author>
<contributor.author>Nanji, A</contributor.author>
<contributor.author>Hou, J</contributor.author>
<contributor.author>Fong, DYT</contributor.author>
<contributor.author>Au, WS</contributor.author>
<contributor.author>Yuen, ST</contributor.author>
<contributor.author>Lin, M</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Lam, SK</contributor.author>
<date.accessioned>2012-10-08T03:10:46Z</date.accessioned>
<date.available>2012-10-08T03:10:46Z</date.available>
<date.issued>2002</date.issued>
<identifier.citation>Journal Of Viral Hepatitis, 2002, v. 9 n. 4, p. 280-287</identifier.citation>
<identifier.issn>1352-0504</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/167738</identifier.uri>
<description.abstract>We examined whether combination therapy with thymosin-&#945;1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation. We studied 32 hepatitis B e antigen positive patients in the immune-tolerant phase of infection, treated with 26-weeks combination therapy of famciclovir and thymosin-&#945;1 (group 1). Thirty-two patients who received 26-weeks famciclovir monotherapy (group 2) and another 32 patients who received no treatment (group 3), served as controls. Peripheral blood mononuclear cell proliferation and cytokine secretion in response to recombinant HBV core and surface antigen and serial serum HBV-DNA, were assayed. No significant difference in adverse events were observed among the three groups. By week 26, the median reduction in group 1 (0.94 log 10 copies/mL) was greater than group 2 (0.70 log 10 copies/mL, P &lt; 0.001). Five (15.6%) patients in group 1 at 52 weeks (median range 13-78 weeks) and none in group 2 or 3 experienced hepatitis B e antigen seroconversion (P = 0.053). Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored.</description.abstract>
<language>eng</language>
<relation.ispartof>Journal of Viral Hepatitis</relation.ispartof>
<subject>Famciclovir</subject>
<subject>HBV</subject>
<subject>Immune tolerant</subject>
<subject>Thymosin-&#945;1</subject>
<title>Thymosin-&#945;1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1046/j.1365-2893.2002.00361.x</identifier.doi>
<identifier.scopus>eid_2-s2.0-0036633685</identifier.scopus>
<identifier.hkuros>78774</identifier.hkuros>
<identifier.hkuros>67333</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036633685&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>9</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>280</identifier.spage>
<identifier.epage>287</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. Nanfang Hospital
  2. The University of Hong Kong
  3. Queen Mary Hospital Hong Kong